DNA (cytosine-5)-methyltransferase 3A

From WikiMD.com Medical Encyclopedia

DNA (cytosine-5)-methyltransferase 3A[edit | edit source]

Simplified domains of DNMT3A isoforms

DNA (cytosine-5)-methyltransferase 3A (DNMT3A) is an enzyme that plays a crucial role in the epigenetic regulation of gene expression in eukaryotic cells. It is part of the DNA methyltransferase family, which is responsible for adding a methyl group to the 5th carbon of the cytosine ring in DNA, a process known as DNA methylation. This modification is essential for normal development, genomic imprinting, and X-chromosome inactivation.

Structure[edit | edit source]

DNMT3A is a large protein that contains several functional domains. The N-terminal region includes a PWWP domain and an ADD domain, which are involved in targeting the enzyme to specific regions of the genome. The C-terminal region contains the catalytic domain responsible for the transfer of methyl groups to DNA. DNMT3A can form complexes with other proteins, such as DNMT3B and DNMT3L, to enhance its activity and specificity.

Function[edit | edit source]

The primary function of DNMT3A is to establish new methylation patterns during embryogenesis and in stem cells. It is also involved in the maintenance of methylation patterns in somatic cells. DNMT3A works in conjunction with DNMT1, which is responsible for maintaining methylation patterns during DNA replication.

Biological Significance[edit | edit source]

DNA methylation is a key epigenetic mechanism that regulates gene expression without altering the DNA sequence. It is involved in various biological processes, including cell differentiation, genomic imprinting, and X-chromosome inactivation. Abnormal methylation patterns are associated with several diseases, including cancer, neurological disorders, and immunological diseases.

Clinical Implications[edit | edit source]

Mutations in the DNMT3A gene have been implicated in various types of cancer, including acute myeloid leukemia (AML). These mutations often result in a loss of function, leading to aberrant methylation patterns and altered gene expression. DNMT3A mutations are also associated with poor prognosis in AML patients.

Interactions[edit | edit source]

Heterotetramer of DNMTs 3A2 and 3B3 and its interactions with nucleosome and linker DNA

DNMT3A interacts with several proteins to modulate its activity and specificity. It forms a complex with DNMT3B and DNMT3L, which enhances its ability to methylate DNA. DNMT3A also interacts with histone-modifying enzymes, such as histone deacetylases (HDACs), to coordinate DNA methylation with histone modifications.

Related Pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD